查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2015174

非小細胞肺癌治療市場：依治療方法、治療階段、生物標記表達及通路分類－2026年至2032年全球市場預測

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line Of Therapy, Biomarker Expression, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非小細胞肺癌治療市場價值將達到 349.8 億美元，到 2026 年將成長至 382.6 億美元，到 2032 年將達到 671.3 億美元，複合年成長率為 9.75%。

主要市場統計數據
基準年 2025 349.8億美元
預計年份：2026年 382.6億美元
預測年份 2032 671.3億美元
複合年成長率 (%) 9.75%

非小細胞肺癌治療的演變：聚焦臨床重點、支付方趨勢和轉化視角

非小細胞肺癌（NSCLC）仍然是臨床腫瘤學領域的核心挑戰，需要整合臨床創新、支付方合作以及營運框架的建構。過去十年來的進展拓展了治療選擇，同時也使決策流程更加複雜，迫使臨床醫生和醫療系統在療效、毒性和長期管理等因素之間尋求平衡。本分析著重探討了治療科學與系統性需求之間的交集，旨在幫助領導者清晰了解當前的情況。

新型治療和診斷創新正在重塑整個非小細胞肺癌治療和研發領域的治療流程和相關人員的獎勵。

非小細胞肺癌（NSCLC）領域正經歷著由科學創新、監管進步和新型醫療服務模式驅動的變革。免疫腫瘤學的進步、標靶治療的最佳化以及聯合治療策略正在改變治療方法順序的標準和大型臨床試驗的設計。同時，監管機構越來越重視生物標記定義的患者群體和核准後證據，加速了分層開發，同時也提高了對診斷能力和真實世界數據基礎設施的需求。

評估 2025 年美國關稅對供應鏈、臨床試驗以及患者獲得非小細胞肺癌治療的影響。

美國2025年實施的關稅政策進一步加劇了非小細胞肺癌（NSCLC）治療藥物的供應鏈、臨床試驗物流和上市後進入的複雜性。關稅帶來的成本壓力將波及活性成分的採購、成品的進口以及生產計劃，可能導致採購延誤，並影響製造商、經銷商和醫療服務提供者的利潤率。這些營運方面的影響將直接波及依賴不間斷供應的臨床項目以及需要跨區域庫存同步的上市活動。

細分分析揭示了管道的動態，顯示了治療方法類型、治療方案的考慮因素、生物標記定義的隊列以及治療方法採用趨勢。

市場區隔的詳細分析揭示了治療方法方案和商業性路徑如何沿著多個維度分支。根據治療方法類型，主要類別包括化療、免疫療法和標靶治療，其中免疫療法可進一步細分為CTLA-4抑制劑、PD-1抑制劑和PD-L1抑制劑。在CTLA-4抑制劑中，Ipilimumab等藥物代表了聯合治療策略中使用的傳統機制；而Nivolumab和Pembrolizumab等PD-1抑制劑，以及Atezolizumab、Avelumab和Durvalumab等PD-L1抑制劑則展現了查核點抑制劑類藥物的廣泛性及其在當前治療方法中的核心作用。標靶治療包括 ALK 抑制劑、BRAF 抑制劑、EGFR 抑制劑和 ROS1 抑制劑，其中 EGFR 抑制劑類別本身發展成為第一代、第二代和第三代藥物，每一代都反映了療效、抗藥性管理以及耐受性的改進。

對非小細胞肺癌 (NSCLC) 治療引入、監管變化和醫療保健系統的區域差異進行比較分析。

區域趨勢對非小細胞肺癌（NSCLC）治療的引入、資金籌措和管理方式有顯著影響。在美洲，報銷途徑和大規模綜合醫療保健系統可能有助於新藥的快速上市，但支付方的要求以及各州處方藥清單核准流程的差異，使得製藥公司必須採取多方面的准入策略。該地區的研究基礎設施支持積極的本地臨床試驗和生物標記主導治療方法的快速應用，但成本效益分析仍然是政策辯論和保險覆蓋決策的重要影響因素。

領先的生物製藥和診斷公司的策略概況，重點關注非小細胞肺癌領域的研發管線差異化、合作模式和商業化方法。

非小細胞肺癌 (NSCLC) 領域的企業策略取決於其如何在產品線差異化、合作模式和商業性執行之間取得平衡。主要企業正大力投資於強大的轉化醫學項目，將作用機制的深入理解與生物標記的開發相結合，從而實現更具針對性的適應症策略，並在競爭中脫穎而出。生物製藥公司、診斷服務提供者和合約研究組織 (CRO) 之間的策略合作，正透過整合互補優勢，加速生物標記的檢驗並擴大臨床試驗的患者招募範圍。

為行業領導者提供實用建議，以最佳化臨床策略、加快治療方法的採用，並調整商業模式，從而提高醫療保健品質。

行業領導者應優先考慮一系列切實可行的措施，將科學進步轉化為永續的臨床和商業性成果。首先，將診斷能力與治療藥物的上市整合至關重要。實施針對ALK、EGFR、PD-L1和KRAS的完善檢測流程，將最大限度地篩選出合適的患者，並縮短治療啟動時間。其次，證據的產生應超越隨機試驗，涵蓋真實世界療效和衛生經濟學分析，從而為醫保報銷談判和基於療效的合約提供支持。

採用嚴謹的混合方法，說明了資料來源、專家訪談以及支持臨床、監管和商業性結論的分析框架。

本研究採用嚴謹的混合研究方法，結合一手和二手研究，整合臨床、監管和商業性的洞見。一手研究包括對腫瘤學家、保險公司和診斷領域領導者的深度專家訪談，以及對保險公司資料的審查和對臨床指南的分析。二手研究涵蓋同行評審文獻、監管申報文件和公開的臨床試驗註冊信息，以支持機制和結果數據。

整合結論，強調策略轉折點、合作的必要性以及改善非小細胞肺癌治療結果的途徑。

總之，綜合分析指出了臨床創新、診斷技術應用和策略性商業性實施相互交匯並影響治療結果的關鍵點。最重要的轉折點包括及時進行生物標記檢測、建立健全的供應鏈網路，以及建立將新型作用機制與患者獲益聯繫起來的證據。重要的合作要素包括與診斷夥伴共同開發、與支付方就真實世界療效指標達成一致，以及建構能夠簡化複雜治療方法啟動和監測的整合式醫療模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 非小細胞肺癌治療市場：依治療方法

  • 化療
  • 免疫療法
    • CTLA-4抑制劑
      • Ipilimumab
    • PD-1抑制劑
      • Nivolumab
      • Pembrolizumab
    • PD-L1抑制劑
      • Atezolizumab
      • Avelumab
      • Durvalumab
  • 分子標靶治療
    • ALK抑制劑
    • BRAF抑制劑
    • EGFR抑制劑
      • 第一代
      • 第二代
      • 第三代
    • ROS1抑制劑

第9章 非小細胞肺癌治療市場：依治療階段分類

  • 第 1 行
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療
  • 第二行
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療
  • 從第三行開始
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療

第10章 非小細胞肺癌治療市場：依生物標記表達分類

  • ALK 重構
  • EGFR突變
  • PD-L1高表達
  • KRAS突變

第11章 非小細胞肺癌治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 非小細胞肺癌治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 非小細胞肺癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非小細胞肺癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：非小細胞肺癌治療市場

第16章 中國：非小細胞肺癌治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3B524

The Non-small Cell Lung Cancer Therapeutics Market was valued at USD 34.98 billion in 2025 and is projected to grow to USD 38.26 billion in 2026, with a CAGR of 9.75%, reaching USD 67.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.98 billion
Estimated Year [2026] USD 38.26 billion
Forecast Year [2032] USD 67.13 billion
CAGR (%) 9.75%

An orientation to the evolving non-small cell lung cancer therapeutic landscape highlighting clinical priorities, payer shifts, and translational prospects

Non-small cell lung cancer (NSCLC) remains a central challenge in oncology practice, requiring a synthesis of clinical innovation, payer alignment, and operational readiness. Advances over the past decade have expanded treatment options and complicated decision pathways, driving clinicians and health systems to balance efficacy, toxicity, and long-term management considerations. This analysis foregrounds the intersection of therapeutic science and system-level imperatives to equip leaders with a clear orientation to the current environment.

The introduction sets the stage by contextualizing recent regulatory approvals, evolving biomarker-driven paradigms, and the impact of combination regimens on practice patterns. It also signals where strategic attention will most likely yield returns: optimizing diagnostic workflows for actionable biomarkers, aligning formulary strategies with real-world outcomes, and investing in evidence generation to support value-based contracting. By framing problems and priorities upfront, the reader gains a concise roadmap for the deeper sections that follow.

Emerging therapeutic and diagnostic innovations reshaping treatment algorithms and stakeholder incentives across non-small cell lung cancer care and development

The NSCLC landscape is undergoing transformative shifts driven by scientific innovation, regulatory evolution, and emergent care delivery models. Immuno-oncology refinements, targeted agent optimization, and combination strategies are changing the calculus for sequencing therapies and for the design of pivotal clinical trials. Concurrently, regulatory bodies increasingly emphasize biomarker-defined populations and post-approval evidence, which accelerates stratified development but raises demands on diagnostic capacity and real-world data infrastructures.

In parallel, payer dynamics and value frameworks are shifting toward outcomes-based arrangements, compelling manufacturers and health systems to integrate health economics and outcomes research earlier in development. Advances in diagnostics, including broader adoption of next-generation sequencing and liquid biopsies, enable more precise patient selection but require investment in lab networks and clinician education. Together, these forces are creating new competitive frontiers where clinical differentiation, diagnostic enablement, and commercial agility determine long-term positioning.

Assessment of 2025 United States tariffs on supply chains, clinical trials, and patient access to non-small cell lung cancer therapies

The introduction of United States tariffs in 2025 has introduced additional complexity across supply chains, trial logistics, and downstream access for NSCLC therapies. Tariff-driven cost pressures ripple through active pharmaceutical ingredient sourcing, finished product imports, and manufacturing schedules, which can create procurement delays and margin sensitivities for manufacturers, distributors, and providers. These operational impacts have direct implications for clinical programs that depend on uninterrupted supply and for launch activities that require synchronized inventory across regions.

Moreover, tariffs can alter the economics of companion diagnostic supply and laboratory consumables, potentially constraining rapid adoption of biomarker testing. Trial sponsors may face increased costs for international site support or for shipping investigational products, prompting protocol adjustments and contingency planning. Health systems and payers responding to increased acquisition costs may tighten utilization controls, which raises the importance of robust real-world evidence to demonstrate comparative value and to preserve patient access. The net effect is a renewed emphasis on supply chain resilience, diversified sourcing strategies, and proactive stakeholder engagement to mitigate access interruptions.

Segmentation analysis revealing treatment type distinctions, therapy line considerations, biomarker-defined cohorts, and channel dynamics informing therapy adoption

A granular view of segmentation reveals how therapeutic choices and commercial pathways diverge across multiple axes. Based on treatment type, core categories include chemotherapy, immunotherapy, and targeted therapy, with immunotherapeutic modalities further delineated into CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors. Within CTLA-4 inhibitors, agents such as ipilimumab exemplify older-class mechanisms used in combination strategies, while PD-1 inhibitors like nivolumab and pembrolizumab, and PD-L1 inhibitors such as atezolizumab, avelumab, and durvalumab, demonstrate the breadth of the checkpoint inhibitor class and its central role in current regimens. Targeted therapy spans ALK inhibitors, BRAF inhibitors, EGFR inhibitors, and ROS1 inhibitors, and the EGFR class itself unfolds across first-, second-, and third-generation agents, each generation reflecting improvements in potency, resistance profile management, and tolerability.

When viewed through the line-of-therapy lens, first-line, second-line, and third-or-later settings each present unique clinical and commercial dynamics, with first-line options encompassing chemotherapy, combination therapy, immunotherapy, and targeted therapy based on biomarker status. Second-line and later lines similarly incorporate chemotherapy, combination regimens, immunotherapy, and targeted approaches, but decisions are heavily influenced by prior exposure, evolving resistance mechanisms, and patient functional status. Biomarker expression further segments patients into groups defined by ALK rearrangement, EGFR mutation, high PD-L1 expression, and KRAS mutation, driving differential eligibility for targeted agents, checkpoint inhibitors, or combinations. Distribution channel segmentation - hospital pharmacy, online pharmacy, and retail pharmacy - shapes patient access, dispensing logistics, and adherence support programs, especially for oral targeted therapies that rely on outpatient distribution. Together, these segmentation dimensions create a complex matrix in which clinical efficacy, diagnostic capacity, and channel execution determine adoption patterns and therapeutic sequencing.

Comparative regional insights into therapeutic adoption, regulatory variation, and healthcare capacity shaping non-small cell lung cancer care across regions

Regional dynamics substantially influence how NSCLC therapeutics are adopted, financed, and administered. In the Americas, reimbursement pathways and large integrated health systems can facilitate rapid adoption of novel agents, but heterogeneity in payer requirements and state-level formulary processes means manufacturers must deploy multifaceted access strategies. The region's research infrastructure supports robust local trial activity and accelerated uptake for biomarker-driven therapies, but affordability debates continue to shape policy discourse and coverage decisions.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and payer models where national health technology assessment processes and centralized approvals interact to create varied timelines for patient access. Countries with established HTA frameworks require early demonstration of comparative effectiveness, while emerging markets within the region emphasize cost containment and may prioritize generics or lower-cost alternatives. Asia-Pacific is characterized by rapid adoption in some high-capacity markets alongside significant variability in diagnostic availability and reimbursement across nations. Variations in population genetics, such as higher prevalence of certain actionable mutations in specific countries, influence clinical trial design and prioritization of targeted agents. Across all regions, local manufacturing capacity, diagnostic networks, and policy environments determine how swiftly new therapeutic paradigms translate into routine care.

Strategic profiles of leading biopharmaceutical and diagnostics companies highlighting pipeline differentiation, partnership models, and commercialization approaches in non-small cell lung cancer

Company strategies in NSCLC are defined by how organizations balance pipeline differentiation, partnership models, and commercial execution. Leading firms invest in robust translational programs to link mechanism-of-action insights with biomarker development, enabling more targeted label strategies and differentiated positioning against competing agents. Strategic collaborations among biopharma, diagnostics providers, and contract research organizations accelerate biomarker validation and expand trial enrollment by leveraging complementary capabilities.

Commercial approaches emphasize integrated patient support, diagnostics enablement, and payer evidence generation. Successful companies align medical affairs, market access, and commercial teams around outcome-based narratives that resonate with health systems and payers. Additionally, firms that demonstrate agility in portfolio management - reallocating resources toward high-value combinations or novel mechanisms - tend to preserve launch momentum and capture clinically relevant niches. Observing competitor behaviors, leaders can identify partnership opportunities, licensing paths, and therapeutic adjacencies that reduce development risk while expanding addressable patient populations.

Actionable recommendations to enable industry leaders optimize clinical strategies, accelerate therapeutic adoption, and align commercial models to improve care

Industry leaders should pursue a set of actionable priorities to convert scientific advances into durable clinical and commercial outcomes. First, integrating diagnostic capacity with therapeutic launches is essential; implementing robust testing pathways for ALK, EGFR, PD-L1, and KRAS will maximize appropriate patient selection and reduce time-to-treatment. Second, evidence generation must extend beyond randomized trials to include real-world effectiveness and health economic analyses that support reimbursement discussions and outcomes-based contracting.

Third, supply chain diversification and contingency planning are critical to mitigate tariff-related and geopolitical risks that can interrupt access. Fourth, leaders should design commercial models that emphasize patient navigation and adherence support, particularly for oral targeted agents distributed through hospital, online, or retail pharmacies. Finally, fostering cross-sector partnerships - between manufacturers, diagnostics providers, payers, and healthcare systems - will accelerate adoption of combination regimens and enable shared-risk arrangements that align incentives around patient outcomes.

Rigorous mixed-method approach describing data sources, expert interviews, and analytical frameworks that inform clinical, regulatory, and commercial conclusions

This research applies a rigorous mixed-method approach combining primary and secondary evidence to synthesize clinical, regulatory, and commercial insights. Primary research included in-depth expert interviews with oncologists, payers, and diagnostics leaders, alongside payer dossier reviews and clinical guideline analyses. Secondary research encompassed peer-reviewed literature, regulatory filings, and publicly available clinical trial registries to corroborate mechanistic and outcomes data.

Analytical frameworks integrated thematic coding of qualitative inputs with triangulation against published efficacy and safety data. Diagnostic prevalence and biomarker distributions were interpreted in the context of population genetics and testing infrastructure. For commercial conclusions, reimbursement pathway analysis and stakeholder feedback were synthesized to derive practical implications. Throughout, methodological safeguards included source cross-validation, transparently documented assumptions, and iterative review with clinical and market access experts to ensure robustness.

Concluding synthesis emphasizing strategic inflection points, collaborative imperatives, and pathways to improve outcomes in non-small cell lung cancer care

The concluding synthesis distills where clinical innovation, diagnostics enablement, and strategic commercial execution converge to influence outcomes. The most consequential inflection points involve timely biomarker testing, resilient supply networks, and evidence generation that links novel mechanisms to meaningful patient benefit. Collaborative imperatives span co-development with diagnostics partners, alignment with payers on real-world outcome metrics, and integrated care models that streamline initiation and monitoring of complex regimens.

Leaders who prioritize these axes concurrently will be better positioned to translate therapeutic potential into sustained patient benefit. The conclusion underscores the need for cross-functional investment, early engagement with reimbursement stakeholders, and continuous learning from real-world outcomes to adapt strategies as new data emerge. By focusing on these practical pathways, organizations can support broad, equitable access to advances in non-small cell lung cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
    • 8.2.1. CTLA-4 Inhibitors
      • 8.2.1.1. Ipilimumab
    • 8.2.2. PD-1 Inhibitors
      • 8.2.2.1. Nivolumab
      • 8.2.2.2. Pembrolizumab
    • 8.2.3. PD-L1 Inhibitors
      • 8.2.3.1. Atezolizumab
      • 8.2.3.2. Avelumab
      • 8.2.3.3. Durvalumab
  • 8.3. Targeted Therapy
    • 8.3.1. ALK Inhibitors
    • 8.3.2. BRAF Inhibitors
    • 8.3.3. EGFR Inhibitors
      • 8.3.3.1. First Generation
      • 8.3.3.2. Second Generation
      • 8.3.3.3. Third Generation
    • 8.3.4. ROS1 Inhibitors

9. Non-small Cell Lung Cancer Therapeutics Market, by Line Of Therapy

  • 9.1. First Line
    • 9.1.1. Chemotherapy
    • 9.1.2. Combination Therapy
    • 9.1.3. Immunotherapy
    • 9.1.4. Targeted Therapy
  • 9.2. Second Line
    • 9.2.1. Chemotherapy
    • 9.2.2. Combination Therapy
    • 9.2.3. Immunotherapy
    • 9.2.4. Targeted Therapy
  • 9.3. Third Or Later
    • 9.3.1. Chemotherapy
    • 9.3.2. Combination Therapy
    • 9.3.3. Immunotherapy
    • 9.3.4. Targeted Therapy

10. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression

  • 10.1. ALK Rearrangement
  • 10.2. EGFR Mutant
  • 10.3. High PD-L1 Expression
  • 10.4. KRAS Mutant

11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Non-small Cell Lung Cancer Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Non-small Cell Lung Cancer Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Non-small Cell Lung Cancer Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Non-small Cell Lung Cancer Therapeutics Market

16. China Non-small Cell Lung Cancer Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amgen Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Bayer AG
  • 17.8. BeiGene, Ltd.
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. F. Hoffmann-La Roche Ltd.
  • 17.11. GlaxoSmithKline plc
  • 17.12. Merck & Co., Inc.
  • 17.13. Novartis AG
  • 17.14. Pfizer Inc.
  • 17.15. Regeneron Pharmaceuticals, Inc.
  • 17.16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. GCC NON-SM